Cedar Brook Financial Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-404
Closed -$366K 18
2024
Q2
$366K Sell
404
-1,144
-74% -$915K 2.75% 7
2024
Q1
$1.2M Buy
1,548
+67
+5% +$47.7K 0.24% 102
2023
Q4
$942K Sell
1,481
-118
-7% -$68.9K 0.21% 121
2023
Q3
$859K Sell
1,599
-628
-28% -$324K 0.22% 108
2023
Q2
$1.04M Buy
2,227
+491
+28% +$206K 0.25% 94
2023
Q1
$596K Sell
1,736
-41
-2% -$13.8K 0.15% 153
2022
Q4
$650K Sell
1,777
-140
-7% -$49.6K 0.18% 136
2022
Q3
$620K Sell
1,917
-425
-18% -$135K 0.2% 133
2022
Q2
$759K Sell
2,342
-148
-6% -$44.4K 0.24% 108
2022
Q1
$713K Sell
2,490
-108
-4% -$27.8K 0.19% 140
2021
Q4
$717K Buy
2,598
+340
+15% +$86.2K 0.18% 132
2021
Q3
$522K Sell
2,258
-99
-4% -$24.4K 0.16% 160
2021
Q2
$541K Buy
2,357
+44
+2% +$8.84K 0.16% 167
2021
Q1
$432K Buy
2,313
+821
+55% +$161K 0.15% 162
2020
Q4
$252K Buy
1,492
+109
+8% +$16.3K 0.09% 252
2020
Q3
$205K Buy
+1,383
New +$214K 0.08% 271
2019
Q4
Sell
-1,874
Closed -$210K 311
2019
Q3
$210K Buy
+1,874
New +$209K 0.09% 277
2019
Q2
Sell
-1,785
Closed -$232K 309
2019
Q1
$232K Buy
+1,785
New +$217K 0.11% 240

Other funds holding LLY

Cedar Brook Financial Partners's LLY Position: Q3 2024 in Review

Cedar Brook Financial Partners sold out of Eli Lilly (LLY) in Q3 2024, closing a stake of 404 shares — an estimated $366K sold.

Cedar Brook Financial Partners first reported a position in LLY in Q1 2019 and held it in 18 quarters. The position peaked at $1.2M in Q1 2024. 3,657 funds tracked by Wall St. Rank hold LLY as of Q3 2024.

  • Cedar Brook Financial Partners reported no remaining Eli Lilly position as of Q3 2024 after selling out during the quarter.
  • Cedar Brook Financial Partners sold 404 Eli Lilly shares in Q3 2024, an estimated $366K.
  • Cedar Brook Financial Partners first reported a position in Eli Lilly in Q1 2019 and held it in 18 quarters.
  • Cedar Brook Financial Partners's Eli Lilly position peaked at $1.2M in Q1 2024.
  • 3,657 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2024.

Based on Cedar Brook Financial Partners's 13F filing for Q3 2024, filed 21 Oct 2024.